A61P 1/16
Drugs for disorders of the alimentary tract or the digestive system: for
Official title: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P1/16 (Drugs for disorders of the alimentary tract or the digestive system: for) appears on 14,735 US grants and 23,766 published applications in this corpus.
Search patents in A61P- Granted patents
- 14,735
- Published applications
- 23,766
- Assignees
- 5,983
- Inventors
- 37,100
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 5 | 0 |
| 1978 | 5 | 0 |
| 1979 | 5 | 0 |
| 1980 | 7 | 0 |
| 1981 | 9 | 0 |
| 1982 | 6 | 0 |
| 1983 | 3 | 0 |
| 1984 | 12 | 0 |
| 1985 | 13 | 0 |
| 1986 | 11 | 0 |
| 1987 | 12 | 0 |
| 1988 | 18 | 0 |
| 1989 | 23 | 0 |
| 1990 | 27 | 0 |
| 1991 | 23 | 0 |
| 1992 | 21 | 0 |
| 1993 | 26 | 0 |
| 1994 | 25 | 0 |
| 1995 | 32 | 0 |
| 1996 | 43 | 0 |
| 1997 | 75 | 0 |
| 1998 | 107 | 0 |
| 1999 | 100 | 0 |
| 2000 | 121 | 0 |
| 2001 | 136 | 49 |
| 2002 | 157 | 287 |
| 2003 | 181 | 485 |
| 2004 | 147 | 757 |
| 2005 | 188 | 803 |
| 2006 | 292 | 769 |
| 2007 | 305 | 962 |
| 2008 | 372 | 1053 |
| 2009 | 452 | 1205 |
| 2010 | 686 | 1515 |
| 2011 | 721 | 1357 |
| 2012 | 876 | 1387 |
| 2013 | 996 | 1151 |
| 2014 | 1020 | 1199 |
| 2015 | 894 | 1173 |
| 2016 | 824 | 1230 |
| 2017 | 866 | 1116 |
| 2018 | 825 | 1115 |
| 2019 | 801 | 1097 |
| 2020 | 737 | 991 |
| 2021 | 665 | 816 |
| 2022 | 478 | 853 |
| 2023 | 400 | 758 |
| 2024 | 360 | 657 |
| 2025 | 392 | 589 |
| 2026 | 232 | 392 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- PHD inhibitor compounds, compositions, and use6 Oct 2026US 12,753,161 B2Akebia Therapeutics, Inc.
- Prime editor system for in vivo genome editing6 Oct 2026US 12,753,397 B2University of Massachusetts
- Methods of treating fibrotic liver diseases or conditions with indeglitazar29 Sep 2026US 12,746,225 B2Pleiogenix Inc.
- Benzimidazole compound for the treatment of metabolic disorders29 Sep 2026US 12,746,227 B2Ache Laboratorios Farmaceuticos S/A
- Combination therapies of FASN inhibitors with thyroid hormone receptor agonists29 Sep 2026US 12,746,242 B2Sagimet Biosciences Inc.
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Functional protective agent for organ or tissue8 Oct 2026US 2026/0306488 A1Jellice Co., Ltd.
- Method of inhibiting adenosine triphosphate secretion, method of inhibiting hepatic stellate cell activation, method of deactivating hepatic stellate cell, method of treating hepatic fibrosis, method of treating non-alcoholic steatohepatitis, and method of treating psoriasis8 Oct 2026US 2026/0306500 A1Kurume University
- Compositions and uses of glp-1-gip receptor agonists8 Oct 2026US 2026/0306588 A1Maison Blaise Labs, LLC
- Crystal form of lanifibranor, preparation method therefor, and use thereof8 Oct 2026US 2026/0308150 A1Inventiva
Most cited
By later US patents
- Retrograde tissue splitter and method1,605US 5,449,355 AValleylab, Inc. · 1995
- Retrograde tissue splitter and method1,585US 5,797,906 AValleylab, Inc. · 1998
- Modular infusion device and method1,554US 6,749,587 B2Insulet Corporation · 2004
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001